Literature DB >> 8951197

A single sample saliva test to determine acetylator phenotype.

A D Hutchings1, P A Routledge.   

Abstract

A comparison was made between the results of acetylator phenotyping by determination of the acetylisoniazid to isoniazid (AcINH/INH) concentration ratio in plasma and in saliva 3 h after oral administration of isoniazid (200mg). In the 154 subjects studied, 68 (44%) were fast acetylators (AcINH/INH ratio > 1.5) using the plasma ratio. In all subjects the saliva AcINH/INH ratio was also > 1.5. Eighty-five of the eighty-six remaining subjects had saliva and plasma AcINH/INH ratios < 1.5 in the 3 h sample. Thus, with one exception there was complete agreement between the acetylator status determined by measurement of saliva or plasma AcINH/INH ratio in a single 3 h sample. Saliva measurement may provide a simple non-invasive alternative to plasma collection in assessing acetylator status.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8951197     DOI: 10.1111/j.1365-2125.1996.tb00121.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  2 in total

1.  The effects of acute ethanol intake on isoniazid pharmacokinetics.

Authors:  R G Dattani; F Harry; A D Hutchings; P A Routledge
Journal:  Eur J Clin Pharmacol       Date:  2004-10-02       Impact factor: 2.953

2.  Clinical standards for the dosing and management of TB drugs.

Authors:  J W C Alffenaar; S L Stocker; L Davies Forsman; A Garcia-Prats; S K Heysell; R E Aarnoutse; O W Akkerman; A Aleksa; R van Altena; W Arrazola de Oñata; P K Bhavani; N Van't Boveneind-Vrubleuskaya; A C C Carvalho; R Centis; J M Chakaya; D M Cirillo; J G Cho; L D Ambrosio; M P Dalcolmo; P Denti; K Dheda; G J Fox; A C Hesseling; H Y Kim; C U Köser; B J Marais; I Margineanu; A G Märtson; M Munoz Torrico; H M Nataprawira; C W M Ong; R Otto-Knapp; C A Peloquin; D R Silva; R Ruslami; P Santoso; R M Savic; R Singla; E M Svensson; A Skrahina; D van Soolingen; S Srivastava; M Tadolini; S Tiberi; T A Thomas; Z F Udwadia; D H Vu; W Zhang; S G Mpagama; T Schön; G B Migliori
Journal:  Int J Tuberc Lung Dis       Date:  2022-06-01       Impact factor: 3.427

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.